The strategic heart of the research lies in how the two pharmacophores are joined. Most previously reported triazole-sulfonamide hybrids connect the two motifs directly through a sulfur-nitrogen linkage or through a simple benzene ring, and flexible alkyl spacers between the units have been explored only to a limited extent. The new study instead employs a rigid phenyl spacer, in which the sulfonamide nitrogen is linked to the triazole ring through a para-substituted benzene bridge attached at the N1-position of the triazole. According to the authors, this architectural choice allows fine control over electronic communication between the two fragments, conformational rigidity of the whole molecule, and the geometry of target-binding interactions — three factors that are critical for optimising biological activity and selectivity. The resulting scaffold, a series of N-(4-(1H-1,2,3-triazol-1-yl)phenyl)arylsulfonamides, had remained comparatively unexplored, and the study was explicitly designed to fill that gap and establish new structure-activity relationships.

The synthetic route is a textbook demonstration of the power of click chemistry, the copper(I)-catalysed azide-alkyne cycloaddition (CuAAC) reaction pioneered by K. Barry Sharpless in 2001 and recognised with the Nobel Prize in Chemistry in 2022. The team began with 4-nitro-1-fluorobenzene, converting it into the corresponding aryl azide by nucleophilic aromatic substitution with sodium azide in dimethylformamide. The electron-withdrawing nitro group activates the ring toward attack by the azide nucleophile, which forms a Meisenheimer sigma-complex before eliminating fluoride to deliver 1-azido-4-nitrobenzene in an excellent 96 percent yield. The azide then underwent the signature CuAAC step with ethyl propiolate, using copper sulfate and sodium ascorbate to generate the active copper(I) catalyst in situ. The copper acetylide intermediate reacts with the azide to form a metallacycle that cyclises and reductively eliminates, producing the 1,4-disubstituted triazole with complete regioselectivity — the hallmark of the click reaction.

From there, the route proceeds through a palladium-catalysed hydrogenation. The nitro group on the triazole-bearing aromatic ring was reduced to an aniline using five percent palladium on charcoal under hydrogen gas at 75 to 80 degrees Celsius, proceeding through sequential nitroso and hydroxylamine intermediates on the catalyst surface with high chemoselectivity. The final sulfonamide bond was forged by treating the amine intermediate with a panel of eight substituted sulfonyl chlorides in the presence of triethylamine. The amine attacks the electrophilic sulfur centre to form a tetrahedral intermediate, which collapses with loss of chloride to give the products. All eight final conjugates, designated 7a through 7h, were obtained as crystalline solids in yields of 83 to 94 percent, and their structures were unambiguously confirmed by infrared spectroscopy, proton and carbon NMR, and high-resolution mass spectrometry, with observed molecular-ion peaks matching calculated values to within a few thousandths of a mass unit.

The choice of substituents was deliberate rather than decorative. Halogen atoms were installed on the sulfonamide ring because halogens are known to increase the lipophilicity of drug-like molecules, easing their passage across microbial cell membranes and promoting intracellular accumulation. Halogens also reshape the electronic distribution of a molecule, enabling stronger interactions with microbial enzymes through hydrogen bonding, hydrophobic contacts and the directional halogen bond, an interaction that has become an increasingly exploited tool in rational drug design. The eight compounds therefore span methyl, fluoro, chloro and dichloro substitution patterns, allowing the team to read out precisely how each modification influences biological performance.

The biological screening covered an unusually wide front. Against four bacterial strains — the gram-negative Escherichia coli and Pseudomonas aeruginosa and the gram-positive Staphylococcus aureus and Streptococcus pyogenes — the series showed moderate activity with a clear tilt toward gram-negative organisms, possibly reflecting differences in cell wall architecture and membrane permeability. Compounds 7c, bearing a para-fluoro group, and 7h, the 2,5-dichloro analogue, each inhibited E. coli with a minimum inhibitory concentration of 50 micrograms per millilitre, approaching the performance of the reference antibiotic chloramphenicol. Against Pseudomonas aeruginosa, the 3,4-dichloro compound 7g led with the same 50 micrograms per millilitre value. Antifungal testing against Candida albicans, Aspergillus niger and Aspergillus clavatus showed the para-chloro compound 7e and the dichloro compound 7h as the most consistent performers, with 7e displaying the broadest profile at minimum inhibitory concentrations between 250 and 500 micrograms per millilitre, though still short of nystatin.

The antiparasitic and antitubercular results sharpened the picture considerably. In a SYBR Green I fluorescence growth-inhibition assay against Plasmodium falciparum, the 2,5-dichloro compound 7h recorded an IC50 of 0.62 micrograms per millilitre, with the 3-fluoro and 3-methyl analogues close behind at 0.68 and 0.70 micrograms per millilitre respectively. Against Mycobacterium tuberculosis H37Rv, evaluated in Löwenstein-Jensen medium, 7h again led the series with a minimum inhibitory concentration of 50 micrograms per millilitre, followed by the 3-methyl and 3-fluoro derivatives at 62.5. The authors are candid that these values remain well short of frontline drugs — quinine and chloroquine in malaria, isoniazid and rifampicin in tuberculosis — underscoring that substantial structural optimisation lies ahead before the scaffold can compete clinically.

To explain the observed trends, the team ran an extensive molecular docking campaign against five biologically relevant targets: the folate-biosynthesis enzyme dihydropteroate synthase, bacterial DNA gyrase, fungal carbonic anhydrase, malarial enoyl-ACP reductase and the mycobacterial sterol 14-alpha-demethylase CYP51. The docking results consistently reproduced the experimental activity ordering across targets, with 7h showing the densest interaction networks — hydrogen bonds to glycine and threonine residues in DHPS, a pi-cation interaction with arginine and putative halogen bonds in DNA gyrase, predicted zinc coordination in fungal carbonic anhydrase, and pi-pi stacking plus halogen bonding in PfENR and CYP51. The picture that emerges is one of multi-target inhibition, in which the triazole ester moiety and the halogenated sulfonamide arm engage complementary regions of each active site. The authors caution, however, that docking scores correlated only moderately with experiment, and that definitive mechanistic claims will require experimental enzyme inhibition assays.

Computational pharmacokinetics added a further layer of encouragement. All eight compounds satisfied standard drug-likeness rules, showed predicted human oral absorption of roughly 80 to 85 percent, moderate lipophilicity rising from 2.4 to 3.1 across the series, favourable Caco-2 and MDCK permeability, and limited blood-brain barrier penetration. Toxicity screening with the ProTox 3.0 web server placed every compound in a moderate oral toxicity class with predicted LD50 values near 500 milligrams per kilogram, and classified all of them as inactive for neurotoxicity, carcinogenicity, mutagenicity and cytotoxicity. One notable discrepancy — a moderate predicted hERG channel interaction in the ADME analysis but no predicted cardiotoxicity in the QSAR assessment — highlights the need for experimental validation. The authors also stress that the biological evaluations are preliminary first-pass investigations. Even so, with a single 2,5-dichloro compound demonstrating activity against four distinct classes of pathogens, and a clear structure-activity map showing chlorine atoms as the decisive lever, the study delivers exactly what early-stage antimicrobial discovery needs: a validated, synthetically accessible scaffold and a precise chemical hypothesis for making it better.

Subject of Research: Design, synthesis and biological evaluation of sulfonamide-linked 1,2,3-triazole conjugates as broad-spectrum antimicrobial and antiparasitic agents

Article Title: Design, synthesis, and biological evaluation of novel sulfonamide-linked 1,2,3-triazole conjugates

Article References: Pagar, D., Shaw, R., Rajani, D., & Patil, S. (2026). Design, synthesis, and biological evaluation of novel sulfonamide-linked 1,2,3-triazole conjugates. Discover Chemistry, 3(1), Article 464. https://doi.org/10.1007/s44371-026-00907-y

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00907-y

Keywords: 1,2,3-triazole, sulfonamide, click chemistry, CuAAC, antimicrobial activity, antimalarial, antitubercular, antifungal, structure-activity relationship, molecular docking, drug resistance, halogen substitution